93534-22-6

Basic information

• Product Name: Ethanone, 1-(3,4-dichlorophenyl)-2-phenyl-
• CAS NO: 93534-22-6
• Molecular Formula: C14H10Cl2O
• Molecular Weight: 265.139
• Mol File: 93534-22-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-(3,4-dichlorophenyl)-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(3,4-dichlorophenyl)-2-phenyl-(93534-22-6)
• EPA Substance Registry System: Ethanone, 1-(3,4-dichlorophenyl)-2-phenyl-(93534-22-6)

Safety Data

• Hazardous Substances Data: 93534-22-6(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-(3,4-dichlorophenyl)-2-phenyl- is a chemical compound that is also known as 1-(3,4-dichlorophenyl)-2-phenyl-ethanone. It is an organic compound with the molecular formula C16H11Cl2O and has a white crystalline appearance. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It may also have applications in research and chemical manufacturing processes. Additionally, it is important to handle this compound with caution as it may pose certain risks to health and the environment.

Upstream product

• 151169-75-4 3,4-dichlophenylboronic acid 
• 103-80-0 phenylacetyl chloride 
• 103-82-2 phenylacetic acid 
• 2905-68-2 methyl 3,4-dichlorobenzoate 
• 100-39-0 benzyl bromide 
• 95392-03-3 2-(3,4-dichlorophenyl)-2-((trimethylsilyl)oxy)acetonitrile 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 4039-32-1 lithium hexamethyldisilazane 

Downstream Products

• 1283117-56-5 6-(3,4-dichlorophenyl)-4-(3-ethoxy-4-hydroxy-5-nitrophenyl)-5-phenyl-3,4-dihydropyrimidin-2(1H)-one 
• 191014-79-6 3-phenyl-4-(3',4'-dichlorophenyl)-4-oxo-2-butenoic acid 

Relevant articles and documents

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

The retinoid X receptors (RXR) are ligand-activated transcription factors involved in multiple regulatory networks as universal heterodimer partners for nuclear receptors. Despite their high therapeutic potential in many pathologies, targeting of RXR has only been exploited in cancer treatment as the currently available RXR agonists suffer from exceptional lipophilicity, poor pharmacokinetics (PK), and adverse effects. Aiming to overcome the limitations and to provide improved RXR ligands, we developed a new potent RXR ligand chemotype based on the nonsteroidal anti-inflammatory drug oxaprozin. Systematic structure-activity relationship analysis enabled structural optimization toward low nanomolar potency similar to the well-established rexinoids. Cocrystal structures of the most active derivatives demonstrated orthosteric binding, and in vivo profiling revealed superior PK properties compared to current RXR agonists. The optimized compounds were highly selective for RXR activation and induced RXR-regulated gene expression in native cellular and in vivo settings suggesting them as excellent chemical tools to further explore the therapeutic potential of RXR.

NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

Isoxazole compounds as cyclooxygenase inhibitors

A class of substituted isoxazolyl compounds is described for use in treating cyclooxygenase-2 related disorders. Compounds of particular interest are defined by Formula I STR1 wherein R1, R2, and R3, are described in the specification.